Sanofi/Organon Arixtra
Executive Summary
Arixtra added to 425 hospital formularies in the U.S. and Europe as of July, Sanofi says. Sanofi/Organon launched Arixtra (fondaparinux) for deep vein thrombosis in the first quarter (1"The Pink Sheet" Dec. 17, 2001, p. 3). While Arixtra sales had a slow start in the first half, "formulary wins are in line with expectations," Sanofi said. The company expects Arixtra to gain full access to the low molecular weight heparin market in 2006; Sanofi estimates its approved use in hospital-based orthopedic surgery provides 14% access...
You may also be interested in...
Organon/Sanofi Arixtra Late January Launch Will Be Supported By 240 Reps
Organon and Sanofi-Synthelabo will launch the injectable antithrombotic Arixtra with 240 sales reps in late January
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.